EcoDrugPlus

Alpha-1a Adrenergic Receptor-Like

Ensembl ID : ENSNFUG00015021130
Gene Symbol: LOC107393699
3 Cross references
202 Possible Orthologues:

Alpha-2 Adrenergic Receptor-Like

Ensembl ID : ENSNFUG00015002093
Gene Symbol: LOC107377377
3 Cross references
157 Possible Orthologues:

Alpha-2b Adrenergic Receptor-Like

Ensembl ID : ENSNFUG00015014444
Gene Symbol: LOC107394177
3 Cross references
174 Possible Orthologues:

Amine Oxidase Copper Containing 1

Ensembl ID : ENSNFUG00015009046
Gene Symbol: AOC1
3 Cross references
231 Possible Orthologues:

Amyloid Beta A4 Protein-Like

Ensembl ID : ENSNFUG00015005228
Gene Symbol: LOC107389838
3 Cross references
205 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSNFUG00015022910
Gene Symbol: APP
3 Cross references
203 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSNFUG00015020749
Gene Symbol: AR
3 Cross references
213 Possible Orthologues:

Androgen Receptor-Like

Ensembl ID : ENSNFUG00015011905
Gene Symbol: LOC107378241
2 Cross references
206 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSNFUG00015020112
Gene Symbol: AGTR1
3 Cross references
198 Possible Orthologues:

Anti-Apoptotic Protein Nr13-Like

Ensembl ID : ENSNFUG00015017452
Gene Symbol: LOC107397176
3 Cross references
128 Possible Orthologues:

Apelin Receptor B-Like

Ensembl ID : ENSNFUG00015021749
Gene Symbol: LOC107388438
3 Cross references
171 Possible Orthologues:

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSNFUG00015002905
Gene Symbol: APEX1
3 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).